People with HIV and hepatitis C virus (HCV) treated for hep C with Harvoni (ledipasvir/sofosbuvir) are cured at similar rates in real-world practice as in clinical trails, aidsmap reports.
Researchers conducted a pooled analysis of clinical trials and real-world cohorts of people with HIV and HCV who were treated for hep C with Harvoni. They presented their findings at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.
The three clinical trials analyzed were ION-4 (327 partcipants), ERADICATE (50 participants) and ANRS HC31 SOFTRIH (68 participants). The four real-world cohorts analyzed were TRIO (150 members), ASCEND (142 members), a Portuguese cohort (166 members) and a U.S. Veterans Affairs (VA) cohort (270 members).
Overall, the rate of those who achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure) was 97 percent for participants of the clinical trials and 94 percent for those in the real-world cohorts. Among African Americans, the overall cure rate was 93 percent in the clinical trials and 92 percent in the real-world cohorts. A respective 98 percent and 97 percent of those who had been treated before were cured, as were a respective 96 percent and 94 percent of those who had cirrhosis of the liver.
To read the aidsmap article, click here.
To read the conference abstract, click here.